Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia — Stella

Home/Immune Thrombocytopenia/Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

View on ClinicalTrials.gov

Recruiting

Back to Immune Thrombocytopenia trials

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

Key details

Phase

Safety & dosing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

Henan Cancer Hospital, Tianjin Medical University Second Hospital

Enrollment target

~60 participants

Started

March 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

6 Years – 18 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.